Leukapheresis Market To Generate Revenue Worth $136.3 Million by 2030

The global leukapheresis market is projected to generate USD 136.3 million revenue by 2030, advancing at a CAGR of 8.4% during 2022–2030. This can be attributed to an increase in the prevalence of hematologic disorders (including leukemia), government initiatives to raise cancer awareness, a notable rise in the count of blood donations worldwide, surge in the pace of technological advancements, and escalation in the demand for leukopaks in a wide range of applications, including pharmaceutical and clinical research.

Leukapheresis Devices To Show Faster Growth

The devices category will witness the faster growth during the prediction period, with a CAGR of around 10%. This is owing due to the rising sales of centrifugal apheresis devices to hospitals for therapy and to blood donation centers for the separation of the components of donated blood, driven by the favorable policies for reimbursement for therapeutic apheresis. For instance, the Spectra Optia apheresis system developed by Terumo BCT collects blood, processes it, and offers therapeutic apheresis, which enables doctors to devote more time to patients. Its combination of the optical detection and continuous-flow centrifugation technologies enables operators to utilize a single platform for a wide range of apheresis procedures.

Component Providers & Blood Centers Dominate Market

Based on end user, blood component providers & blood centers held the largest share in 2022, and they will continue to maintain their leadership status over the projection period. This is due to the rise in the incidence of leukemia, for which chemotherapy is frequently prescribed. Moreover, since patients who receive this therapy may have a temporary immune system and blood cell impairment, they need fresh blood and its components, such as plasma and fresh WBCs. Thus, the rise in the number of donors approaching blood centers is driving the market in this end user category.

Therefore, there is a growing need for the separation of the blood’s components on a global level. Additionally, both developed and developing nations have placed a greater emphasis on blood donation, as a result of which large-scale donation camps are now held in numerous nations and various NGOs have been founded with the assistance of governing bodies and regulatory agencies for this purpose.

Furthermore, hospitals & transfusion centers are expected to register the highest CAGR during the coming period. This will mainly be due to the rapid rise in the count of blood cancer patients and the setup of new hospitals and blood transfusion centers by governments, as a result. In cancer patients, healthy WBCs are transfused with the help of leukapheresis, which is a key factor that will drive the market over the forecast period.

Geographically, North America has the largest share in the leukapheresis market, due to its advanced healthcare infrastructure and the rise in the cases of leukemia. In addition, companies are taking initiatives to launch innovative products in the continent. For instance, in December 2021, Discovery Life Sciences Inc. acquired In Vitro ADMET Laboratories LLC to broaden the range of biospecimen products. This acquisition has allowed the former company to provide researchers with access to a large hepatocyte inventory and associated technologies at scale.

Moreover, the European region will witness significant growth in the leukapheresis market due to its steady economic growth and strong healthcare focus. Germany is an attractive market in the region due to its advanced healthcare infrastructure and presence of a large number of life sciences and medical device companies.

Some of the major market players are Asahi Kasei Medical Co. Ltd., FRESENIUS SE & CO. KGaA, Haemonetics Corporation, Macopharma, Terumo BCT Inc., B. Braun Melsungen AG, STEMCELL Technologies Inc., Precision Medicine Group LLC, and BioIVT LLC.